

SINGAPORE MEDICAL GROUP LIMITED
(Company Registration No.: 200503187W)

USE OF PROCEEDS FROM THE RIGHTS ISSUE

The Board of Directors (the “**Board**”) of Singapore Medical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s announcements dated 1 March 2018, 9 May 2018, 6 June 2018, 18 June 2018, 10 July 2018 and 11 July 2018 (the “**Rights Issue Announcements**”) and the Offer Information Statement (“**OIS**”) dated 18 June 2018 issued by the Company in relation to the renounceable non-underwritten rights issue of up to 23,341,800 new ordinary shares in the issued share capital of the Company, at an issue price of S\$0.48 for each Rights Share, on the basis of one (1) Rights Share for every twenty (20) existing ordinary shares in the issued share capital of the Company held by entitled shareholders as at the books closure date, fractional entitlements to be disregarded (the “**Rights Issue**”).

All capital terms used and not defined herein shall have the same meanings given to them in the Rights Issue Announcements and the OIS, unless otherwise expressly stated or the context otherwise requires.

The Board wishes to announce that out of the net proceeds of S\$6.6 million from the Rights Issue, the Company has utilised S\$0.4 million in the manner as set out below:

<u>Use of Net Proceeds</u>	Allocation of Net Proceeds	Net Proceeds utilised from 10 July 2018 to 23 October 2018	Balance of Net Proceeds as at 23 October 2018
	S\$ million	S\$ million	S\$ million
(i) Merger and acquisitions	4.6	-	4.6
(ii) Growing existing business	2.0	0.4	1.6
	6.6	0.4	6.2

The above use of proceeds for growing existing business of S\$0.4 million is in relation to the purchase of medical equipment and renovation.

The above use of proceeds is in accordance with the intended use as stated in the Rights Issue Announcements and the OIS.

The Company will continue to make periodic announcements via SGXNET upon utilisation of the remaining Rights Issue Proceeds as and when the funds are materially disbursed.

By Order of the Board

Dr Beng Teck Liang
Executive Director and Chief Executive Officer
23 October 2018

This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, CIMB Bank Berhad, Singapore Branch (the “Sponsor”), for compliance with the relevant rules of the SGX-ST, this being the SGX-ST Listing Manual Section B: Rules of Catalyst. The Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.